London East Medical Centre
295 Saskatoon St., London, ON, N5W 6A2(519) 659-4040Monday - Thursday: 9am - 5pmFriday: 9am - 3pm
- Physician-led: two clinical investigators on site
- Every study is reviewed by a research ethics board before it opens
- Run under Health Canada regulations and ICH Good Clinical Practice
- What you submit goes only to this site’s research team
Studies you could join at this site
1 study is recruiting here now.
About this research site
Dr. Peter Dzongowski and his professional team at Milestone Research have been offering clinical trials to London area patients since 1997. In addition to his busy family practice and research office, Dr. Dzongowski is a certified pilot and aviation enthusiast; he also enjoys skiing and sailing in his spare time. The research office is open Monday to Thursday from 9am to 5pm and Friday from 9am to 3pm. If you are interested in a study but cannot make it in during regular business hours, ask the research team about arranging an after-hours appointment.
The people who would look after you
The investigators below are responsible for the studies run at this site, supported by the research team who coordinate your visits. These are the people you would meet.
Family physician since 1993 and a graduate of Western University's Schulich School of Medicine and Dentistry, with privileges at St. Joseph's Health Care London and London Health Sciences Centre. Has taken part, as a study doctor, in large international trials of diabetes, heart, weight-loss and vaccine treatments.
Family physician and a graduate of Western University's Schulich School of Medicine and Dentistry, certified in family medicine since 2014. Works alongside Dr. Dzongowski on the studies running at this site, sharing responsibility for participant care and study visits.
- TaraSenior clinical research coordinator
- AndreaClinical research coordinator
- MichelleClinical research nurse
- MariaClinical research coordinator
Getting here, and what a first visit looks like
Friday: 9am - 3pm
- 1A phone call firstA coordinator calls to go through your health history and answer your questions. Nothing is booked until you want it to be.
- 2Informed consentThe team walks through the study in plain language, including what is being tested and the known risks.
- 3Screening checksSimple tests confirm whether the study is a fit. Being screened does not commit you to taking part.
- 4Your decisionYou choose whether to continue, and you can stop at any point without affecting your regular care.
Inside the clinic
6 photos, scroll for more





What this site has done
Therapeutic experience
Areas of medicine studied at this site, based on data from 1997 to 2026.
How research started here
- 1997Research begins in LondonDr. Dzongowski began leading clinical trials for London-area patients in 1997, alongside his family practice. The research office now trades as Milestone Research.
- Today1 study enrolling in LondonAcross 15 areas of medicine.
Published research and recognition
Peer-reviewed publications and public recognition involving this site’s investigators. Each link opens the original source on another website.
- 2025Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesNew England Journal of Medicine. 2025;393(24):2409-2420 · Lead author: Stephen J. Nicholls, for the SURPASS-CVOT Investigators
Results of SURPASS-CVOT, a trial of more than 13,000 people with type 2 diabetes and heart or blood vessel disease. Tirzepatide protected the heart at least as well as dulaglutide, an established diabetes medicine: heart attack, stroke or death from heart disease occurred in 12.2% vs 13.1% of people. Dr. Dzongowski was one of the trial's investigators.
Read the source (opens in a new tab) - 2025Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical TrialJAMA. 2025;334(1):46-55 · Lead author: Akshay S. Desai, for the KARDIA-2 Study Group
Results of KARDIA-2, a trial of 663 adults whose blood pressure was not controlled by one standard medicine. Adding a single injection of zilebesiran lowered 24-hour systolic blood pressure by a further 4.5 to 12 mm Hg, depending on the medicine it was added to. Some side effects, such as high potassium and low blood pressure, were more common but mostly mild. Dr. Dzongowski and Dr. Sinclair were among the trial's investigators.
Read the source (opens in a new tab) - 2023Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsNew England Journal of Medicine. 2023;388(7):595-608 · Lead author: Alberto Papi, for the AReSVi-006 Study Group
Results of a trial of 24,966 adults aged 60 or older. One dose of an RSV vaccine was about 83% effective at preventing RSV lung infections, and about 94% effective against severe cases, over about 7 months. Dr. Dzongowski was one of the trial's investigators.
Read the source (opens in a new tab) - 2022Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trialTranslational Psychiatry. 2022;12:101 · Lead author: Arun K. Tiwari
A Canadian trial testing whether a genetic test, which shows how a person's body processes antidepressants, can help doctors choose depression treatment. The improvements seen were in line with a larger US trial, and the authors concluded the test can be a useful tool for guiding depression treatment in Canada. Dr. Dzongowski is one of the paper's authors.
Read the source (opens in a new tab) - 2016Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy studyJournal of Clinical Pharmacy and Therapeutics. 2016;41(6):695-702 · Lead author: S. E. Kjeldsen
A one-year international study of a single pill combining two blood pressure medicines, nifedipine and candesartan, in people with moderate to severe high blood pressure. The pill was generally well tolerated and lowered blood pressure by about 30/13 mm Hg on average. Dr. Dzongowski is one of the paper's authors.
Read the source (opens in a new tab)
Research here becomes medicine everywhere
Clinical studies are funded by the companies developing the treatment being tested. The companies below have sponsored research at this site, and many of them have gone on to bring new medicines to Canadians. A name here does not mean one of their studies is enrolling right now, and it is not an endorsement of any product.
Acasti, Assurex Health, Avillion, Carbylan, Dimethaid, Furiex Pharmaceuticals, IDB, Intarcia, Janssen, Labopharm, Metabolex, Phenomix, Trial Management Group Inc., Viveve
- Forxiga
- Lantus / Toujeo
- Ozempic / Wegovy / Rybelsus
- Awiqli
- Onglyza
- Trajenta
- Tresiba
- Arexvy
- Prevnar 20
- Tamiflu
- Capvaxive
- Trumenba
- Vaxneuvance
- Pradaxa
- Edarbyclor
- Twynsta
- Verapamil
- Celebrex
- Prolia
- Butrans
- Febuxostat
- Pennsaid
- Pentosan polysulfate
- Tridural / Zytram XL
- Mounjaro / Zepbound
- Repatha
- Nilemdo
- Advair
- Dupixent
- Trelegy
- Alvesco
- Anoro
- Arnuity
- Breo
- Grastek
- Ultibro
- Aricept
- Imitrex
- Nurtec ODT
- Relpax
- Rexulti
- Viberzi
- DDAVP
- Eucrisa
- Varenicline
- Veozah
A medicine is listed because it was part of at least one study at this site. This is not a recommendation: only your own doctor can say whether a medicine is right for you.
Questions about this site
Do I need a referral from my family doctor?
I am not a patient at this clinic. Can I still take part?
Will taking part cost me anything?
How far will I have to travel?
What happens to the information I submit?
Ask London East Medical Centre to contact you
Phone(519) 659-4040
- Physician-led: two clinical investigators on site
- Every study is reviewed by a research ethics board before it opens
- Run under Health Canada regulations and ICH Good Clinical Practice
- What you submit goes only to this site’s research team

